|
Volumn 14, Issue 3, 2008, Pages 370-382
|
Avonex Combination Trial in relapsing-remitting MS: Rationale, design and baseline data
a b a c d e a a f a g a a a a h a d
d
BIOGEN
(United States)
|
Author keywords
Clinical trial; Interferon beta 1a; Methotrexate; Methylprednisolone; Multiple sclerosis
|
Indexed keywords
BETA1A INTERFERON;
GADOLINIUM;
INTERFERON ANTIBODY;
METHOTREXATE;
METHYLPREDNISOLONE;
PLACEBO;
ADULT;
ARTICLE;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONTRAST ENHANCEMENT;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COOPERATION;
DISEASE ACTIVITY;
DRUG INDUSTRY;
DRUG SAFETY;
EXPANDED DISABILITY STATUS SCALE;
FACTORIAL DESIGN;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MEDICAL RESEARCH;
MONOTHERAPY;
MULTICENTER STUDY;
MULTIPLE SCLEROSIS;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATIENT SELECTION;
PHASE 4 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
RELAPSE;
TREATMENT OUTCOME;
ADJUVANTS, IMMUNOLOGIC;
ADOLESCENT;
ADULT;
ANTI-INFLAMMATORY AGENTS;
COOPERATIVE BEHAVIOR;
DATA INTERPRETATION, STATISTICAL;
DISABILITY EVALUATION;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
INTERFERON-BETA;
MAGNETIC RESONANCE IMAGING;
MALE;
METHOTREXATE;
METHYLPREDNISOLONE;
MIDDLE AGED;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
PATIENT SELECTION;
TREATMENT OUTCOME;
|
EID: 43549110503
PISSN: 13524585
EISSN: None
Source Type: Journal
DOI: 10.1177/1352458507083189 Document Type: Article |
Times cited : (19)
|
References (59)
|